Chan W Y, Wo N C, Cheng L L, Manning M
Department of Pharmacology, Cornell University Medical College, New York, New York, USA.
J Pharmacol Exp Ther. 1996 May;277(2):999-1003.
Substitution of Asn5 in oxytocin (OT) or vasopressin (VP) invariably leads to a dramatic loss of the biological activities of the peptides. Because of this observation, few structure-activity-relationship studies of OT and VP peptides have involved modifications in the 5 position. It is now recognized that peptide agonists and antagonists may use different structural and conformational features in their interactions with the receptors. Our prior studies showed that OT and VP antagonists, unlike the agonists, tolerate amino acid substitutions in the 5 position. This opens new approaches for the design of antagonists. We describe the effects of isosteric replacement of Asn5 by diaminopropionic acid (Dap) or diaminobutyric acid (Dab) in three OT and VP antagonists: (1) the V1a (vasopressor receptor) antagonist d(CH2)5[Tyr(Me)2]AVP; (2) the OT (uterine OT receptor) antagonist d(CH2)5[Tyr(Me)2, Thr4, Tyr-NH29] OVT and (3) three selective OT antagonists, desGly-NH2,d(CH2)5[D-Tyr2, Thr4]OVT, desGly-NH2, d(CH2)5[D-Phe2, Thr4]OVT and desGly-NH2, d(CH2)5- [D-Trp2, Thr4]OVT. The Dap5 and Dab5 substitutions were tolerated remarkably well, with the less isosteric Dap5 substitution leading to a greater retention of anti-OT potency than the Dab5 substitution. Furthermore, the Dap5 and Dab5 and OT and VP antagonist analogues were surprisingly shown to be much more selective than their respective parent compounds. The Dab5 analogue of (1) was devoid of anti-OT activity. The three Dap5 analogues of (3) were devoid of anti-V1a activities. These appear to be the first single-receptor-type-selective OT and VP antagonists discovered to date. These findings could provide new leads for the development of single-receptor-type-selective receptor probes for the localization and characterization of OT and VP receptors and potential selective tocolytics for the treatment of premature labor.
催产素(OT)或血管加压素(VP)中Asn5的取代总是会导致这些肽的生物活性急剧丧失。基于这一观察结果,很少有关于OT和VP肽的构效关系研究涉及5位的修饰。现在人们认识到,肽激动剂和拮抗剂在与受体相互作用时可能使用不同的结构和构象特征。我们之前的研究表明,与激动剂不同,OT和VP拮抗剂能够耐受5位的氨基酸取代。这为拮抗剂的设计开辟了新途径。我们描述了在三种OT和VP拮抗剂中用二氨基丙酸(Dap)或二氨基丁酸(Dab)等排取代Asn5的效果:(1)V1a(血管升压素受体)拮抗剂d(CH2)5[Tyr(Me)2]AVP;(2)OT(子宫OT受体)拮抗剂d(CH2)5[Tyr(Me)2, Thr4, Tyr-NH29]OVT;以及(3)三种选择性OT拮抗剂,desGly-NH2,d(CH2)5[D-Tyr2, Thr4]OVT、desGly-NH2, d(CH2)5[D-Phe2, Thr4]OVT和desGly-NH2, d(CH2)5- [D-Trp2, Thr4]OVT。Dap5和Dab5取代的耐受性非常好,等排性较低的Dap5取代比Dab5取代能更好地保留抗OT效力。此外,令人惊讶的是,Dap5和Dab5以及OT和VP拮抗剂类似物比它们各自的母体化合物具有更高的选择性。(1)的Dab5类似物没有抗OT活性。(3)的三种Dap5类似物没有抗V1a活性。这些似乎是迄今为止发现的首批单受体类型选择性OT和VP拮抗剂。这些发现可为开发用于OT和VP受体定位与表征的单受体类型选择性受体探针以及用于治疗早产的潜在选择性宫缩抑制剂提供新的线索。